56124-62-0
基本信息
ad32
antibioticad32
nsc-246131
n-trifluoroacetyladriamycin-14-valerate
n-trifluoroacetyladriamycin14-valerate
n-trifluoroacetyldoxorubicin14-valerate
trifluoroacetyl-adriamyci14-valerate
trifluoroacetyladriamycin-14-valerate
Pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-a-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl este r
Vinorelbine (BICINS )
[2-Oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
(8S,10S)-8-(Valeryloxymethylcarbonyl)-10-[(3-trifluoroacetylamino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
物理化学性质
| 熔点 | 116-117 °C |
| 沸点 | 135-136 C |
| 密度 | 1.3473 (estimate) |
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 酸度系数(pKa) | 7.34±0.60(Predicted) |
| 形态 | 固体 |
| 颜色 | 红色 |
| 水溶解性 | insoluble |
| 水溶解性 | 不溶 |
| InChIKey | ZOCKGBMQLCSHFP-XGMQQLFPNA-N |
| SMILES | C12=C(O)C3=C(C(=O)C4C=CC=C(OC)C=4C3=O)C(O)=C1C[C@@](O)(C(=O)COC(=O)CCCC)C[C@@H]2O[C@@H]1O[C@H]([C@@H](O)[C@@H](NC(=O)C(F)(F)F)C1)C |&1:21,34,36,38,39,41,r| |
安全数据
| 危险性符号(GHS) |   GHS08,GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H351-H340-H312-H332-H360-H301 |
| 防范说明 | P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P310-P321-P330-P405-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-37/39 |
| 海关编码 | 2941906000 |
| 毒害物质数据 | 56124-62-0(Hazardous Substances Data) |
| 毒性 | dnd-hmn:lym 3 mg/L CJBIAE 58,720,80 |
常见问题列表
| Target | Value |
|
TPA-activated PKC
(Cell-free assay) | 0.85 μM |
|
PDBu-activated PKC
(Cell-free assay) | 1.25 μM |
Valrubicin (AD 32) is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC 50 s of 0.85 and 1.25 μM, respectively. Valrubicin inhibits the binding of [ 3 H]PDBu to PKC. Therefore, Valrubicin competes with the tumor promoter for the PKC binding site and prevents the latter from both interacting with the phospholipid and binding to PKC. Valrubicin shows cytotoxic activity against squamous cell carcinoma (SCC) cell line colony formation, with IC 50 s and IC 90 s of 8.24 ± 1.60 μM and 14.81 ± 2.82 μM for UMSCC5 cells, 15.90 ± 0.90 μM, 29.84 ± 0.84 μM for UMSCC5/CDDP‡ cells, and 10.50 ± 2.39 μM, 19.00 ± 3.91 μM for UMSCC10b cells, respectively. Moreover, Valrubicin in combination with radiation enhances the cytotoxicity.
Valrubicin (3, 6, or 9 mg) reduces tumor growth at week 3 by intratumoral jection in hamster. Valrubicin (6 mg) combined with minimally cytotoxic irradiation (150, 250, or 350 cGy) causes significant tumor shrinkage in hamster. Valrubicin (0.1 μg/μL) significantly reduces the number of infiltrating neutrophils in biopsies challenged with TPA at 24 h and attenuates chronic inflammation in mice. Valrubicin also decreases the expression levels of inflammatory cytokines in the acute model.